In the 1960s, Krasnov 1 began to develop what became known as 'non-penetrating glaucoma surgery' (NPGS). The 'sinusotomy' he described consisted of de-roofing Schlemm's canal from 10-2 o'clock via an external approach and then covering the canal with conjunctiva.
<5 mmHg and 47 % with iridocorneal touch, both at two days post-operatively. Despite these rates of complications occurring early in the post-operative period, trabeculectomy became established as the technique of choice for glaucoma. It was considerably safer than its predecessors, namely anterior and posterior lip sclerectomy, iridencleisis, and posterior lip sclerectomy with or without cautery.
Today, post-trabeculectomy complication rates are far less high than these owing to improvements in surgical technique. At the time, however, they were the benchmark, driving the search for an alternative. Koslov's deep sclerectomy was appealing.
Ideal surgery would create consistently an immediate, controlled IOP reduction with stable visual acuity and a minimal surgical learning curve.
A realistic goal would be an operation that did not give rise to problems associated with early hypotony, late leaks, cataract formation or endophthalmitis, one that necessitated infrequent follow-up and was not bleb-dependent for success. DS and viscocanalostomy (VC) represent attempts to achieve this goal. In particular, VC aims to be bleb-free. Both operations may provoke less post-operative inflammation than trabeculectomy surgery, 8 with smaller amounts of post-operative steroids required. These advantages translate into less intensive follow-up than following trabeculectomy.
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Where are the Problems with Non-penetrating Glaucoma Surgery?
NPGS may be less effective to control IOP than trabeculectomy. Another challenge is the relative complexity of these procedures compared with trabeculectomy. A high level of skills is required to dissect a longer scleral flap of uniform thickness and to create a trabeculo-Descemet Table 1 . 
5-FU = 5-fluorouracil; DS = deep sclerectomy; DSI = DS + implant; DSMMC = DS + mitomycin C; GP = goniopuncture; IOP = intraocular pressure; MMC = mitomycin C; Phaco = phacoemulsification; VC = viscocanalostomy; VCc = VC + canaloplasty; VCMMC = VC + mitomycin C; § = plus needling procedure.

Deep Sclerectomy
Deep Sclerectomy Alone Deep Sclerectomy + Implant (DSI) 
Deep Sclerectomy and Post-operative Infection
There have been two reports of blebitis after DS. 20, 21 There has been one report of endophthalmitis following DSMMC, where intra-operative perforation of the TDW had occurred. 20 There have been no reports of endophthalmitis following DS. 22 This is in contrast to augmented trabeculectomy, where post-operative infection, although rare, remains a risk.
Viscocanalostomy
Viscocanalostomy Alone
Cannulation of Schlemm's canal and injection of an ophtalmic viscoelastic device (OVD) dilate both Schlemm's canal and collector channels and also disrupt the Schlemm's canal wall. 23 Given that the luminal diameter of Schlemm's canal is large, it does not provide resistance to aqueous outflow; 24 hence its dilatation is unlikely to 
Viscocanalostomy and Blebs
Some surgeons who carry out VC observe post-operative drainage blebs, whereas others do not. Stegmann's 13 where three-year results were 59 % and 76 %, respectively. Wishart and Concomitant cataract surgery through same-site incision may improve short-to-medium-term success rates of VC surgery.
Combined Cataract Extraction and Deep Sclerectomy
Unlike PhacoVC, combined cataract extraction and DS (PhacoDS) through the same site would likely increase the risks of hypotony and flat anterior chambers, as there would no longer be a 'guarding' effect from an intact TDW. [33] [34] [35] [36] Perhaps excessive inflammation generated during phacotrabeculectomy leads to increased probability of surgical failure.
Concomitant cataract extraction with DS may improve short-term success rates of DS surgery.
Cataract Extraction + Deep Sclerectomy + Mitomycin C (PhacoDSMMC)
Anand and Lewis et al. 38 published three-year success rates of 40 % (n=89, success ≤21 mmHg), while their 12-month success rate was 57 % (n=91, success ≤21 mmHg). They also published a three-year success rate of 78 % (n=27, success ≤21 mmHg) when combined with cataract surgery.
VCc can achieve excellent success rates in the short term. Excellent medium-term success rates can be obtained with concomitant cataract extraction. Whether these results are better than VC and PhacoVC remains to be determined.
Who Should Undergo Deep Sclerectomy or Viscocanalostomy?
What is a surgeon's motivation not to perform a trabeculectomy? Is it early hypotony or flat anterior chambers? Is it late bleb leaks or late endophthalmitis and a wish to avoid using MMC? (And if so, can the patient afford collagen/hyaluronic acid implants?) Is it to minimize post-operative care? The answers to these questions will determine which alternative to trabeculectomy may be optimal.
Glaucoma
U S O P H T H A L M I C R E V I E W
What Does the Lead Author Do?
With limited although similar experience in both VC/PhacoVC and trabeculectomy surgery, the lead author's preferred surgical techniques are indicated as follows.
Trabeculectomy and MMC for:
• uncontrolled open-angle glaucoma with severe damage;
• open-angle glaucoma with damage occurring at modest IOP levels;
• neovascular glaucoma that is quiescent;
• severe chronic angle-closure glaucoma with separate-site phacoemulsification; and
• abnormal-angle anatomy.
PhacoVC/VC for:
• uncontrolled open-angle glaucoma with moderate damage;
• uveitic glaucoma (to reduce post-operative hypotony and inflammation);
• chronic angle-closure glaucoma with moderate damage;
• patient who would otherwise undergo phacotrabeculectomy;
• only eye;
• split fixation;
• uncontrolled ocular hypertension;
• controlled glaucoma in a patient undergoing cataract surgery who wishes to avoid medication; and
• patient unhappy on topical hypotensives.
When very low IOP is the target, augmented trabeculectomy surgery offers the best chance of success. The question is not whether trabeculectomy can achieve lower IOPs; the question is, lower IOP at what cost in terms of risk of complications? By offering surgery earlier in the course of the disease (when possible) when the target IOP might be higher, it is possible to choose a safer alternative to trabeculectomy.
If the target IOP is higher, then the success rate of any surgery is higher. Figure 1 summarizes these points. By adopting this paradigm, more patients would undergo glaucoma surgery earlier in their disease process. Whereas, a lot of the time, trabeculectomy is a necessity, VC or DS may be an option.
PhacoVC/VC could be offered earlier in the course of the disease, even when glaucoma is not progressive; if a stable glaucoma patient requires cataract extraction, the patient could be offered PhacoVC in an attempt to discontinue topical hypotensives. If the patient does not like using topical hypotensives, PhacoVC/VC can be considered.
While a low target IOP and/or inability to consider ongoing hypotensives argues for augmented trabeculectomy, post-operative complications that might be visually dangerous support VC and DS as options.
Conclusions in 2012
As the level of evidence is mainly moderate to weak, it would be dangerous to conclude too much. Regarding DS, the addition of an 
